Menu
GeneBe

FA2H

fatty acid 2-hydroxylase, the group of Fatty acid hydroxylase domain containing

Basic information

Region (hg38): 16:74712954-74774831

Previous symbols: [ "FAXDC1", "SPG35" ]

Links

ENSG00000103089NCBI:79152OMIM:611026HGNC:21197Uniprot:Q7L5A8AlphaFoldGenCCjaxSfariGnomADPubmedClinVar

Phenotypes

GenCC

Source: genCC

  • hereditary spastic paraplegia 35 (Strong), mode of inheritance: AR
  • hereditary spastic paraplegia 35 (Supportive), mode of inheritance: AR
  • hereditary spastic paraplegia 35 (Definitive), mode of inheritance: AR
  • hereditary spastic paraplegia 35 (Strong), mode of inheritance: AR

Clinical Genomic Database

Source: CGD

ConditionInheritanceIntervention CategoriesIntervention/Rationale Manifestation CategoriesReferences
Spastic paraplegia 35, autosomal recessive, with or without neurodegenerationARGeneralGenetic knowledge may be beneficial related to issues such as selection of optimal supportive care, informed medical decision-making, prognostic considerations, and avoidance of unnecessary testingBiochemical; Neurologic18463364; 19068277; 20104589; 20853438; 22146942; 22925154; 23745665; 24359114

ClinVar

This is a list of variants' phenotypes submitted to ClinVar and linked to the FA2H gene.

  • Spastic paraplegia (202 variants)
  • Hereditary spastic paraplegia 35 (111 variants)
  • not provided (82 variants)
  • Hereditary spastic paraplegia (26 variants)
  • not specified (24 variants)
  • Inborn genetic diseases (16 variants)
  • Neurodegeneration with brain iron accumulation (3 variants)
  • Spastic ataxia (1 variants)
  • See cases (1 variants)

Variants pathogenicity by type

Statistics on ClinVar variants can assist in determining whether a specific variant type in the FA2H gene is commonly pathogenic or not.

In the table, we include only reliable ClinVar variants with their consequences to MANE Select, Mane Plus Clinical transcripts, or transcripts with TSL equals 1. Click the count to view the source variants.

Warning: slight differences between displayed counts and the number of variants in ClinVar may occur, primarily due to (1) the application of a different transcript and/or consequence by our variant effect predictor or (2) differences in clinical significance: we classify Benign/Likely benign variants as Likely benign and Pathogenic/Likely pathogenic variants as Likely pathogenic.

Variant type Pathogenic Likely pathogenic VUS Likely benign Benign Sum
synonymous
6
clinvar
50
clinvar
6
clinvar
62
missense
5
clinvar
9
clinvar
92
clinvar
8
clinvar
1
clinvar
115
nonsense
8
clinvar
2
clinvar
10
start loss
2
clinvar
2
frameshift
9
clinvar
3
clinvar
1
clinvar
13
inframe indel
1
clinvar
3
clinvar
4
splice donor/acceptor (+/-2bp)
5
clinvar
5
splice region
1
6
3
1
11
non coding
22
clinvar
34
clinvar
22
clinvar
78
Total 25 19 124 92 29

Highest pathogenic variant AF is 0.0000132

Variants in FA2H

This is a list of pathogenic ClinVar variants found in the FA2H region.

You can filter this list by clicking the number of variants in the Variants pathogenicity by type table.

Position Type Phenotype Significance ClinVar
16-74713002-T-C Hereditary spastic paraplegia 35 Uncertain significance (Jan 13, 2018)320463
16-74713059-T-G Hereditary spastic paraplegia 35 Benign (Jan 13, 2018)320464
16-74713061-C-T Hereditary spastic paraplegia 35 Benign (Jan 13, 2018)320465
16-74713116-C-T Hereditary spastic paraplegia 35 Uncertain significance (Jan 13, 2018)885528
16-74713126-G-C Hereditary spastic paraplegia 35 Benign (Jan 12, 2018)320466
16-74713232-G-A Hereditary spastic paraplegia 35 Likely benign (Jan 12, 2018)320467
16-74713279-G-T Hereditary spastic paraplegia 35 Uncertain significance (Jan 13, 2018)320468
16-74713303-A-T Hereditary spastic paraplegia 35 Uncertain significance (Jan 13, 2018)320469
16-74713305-C-A Hereditary spastic paraplegia 35 Uncertain significance (Jan 13, 2018)886553
16-74713369-G-C Hereditary spastic paraplegia 35 Likely benign (Jan 13, 2018)320470
16-74713377-G-A Hereditary spastic paraplegia 35 Likely benign (Jan 13, 2018)320471
16-74713407-C-T Hereditary spastic paraplegia 35 Likely benign (Jan 13, 2018)320472
16-74713418-G-T Hereditary spastic paraplegia 35 Uncertain significance (Jan 13, 2018)320473
16-74713537-C-T Hereditary spastic paraplegia 35 Uncertain significance (Jan 13, 2018)320474
16-74713538-G-A Hereditary spastic paraplegia 35 Uncertain significance (Jan 12, 2018)320475
16-74713544-A-C Hereditary spastic paraplegia 35 Uncertain significance (Jan 13, 2018)320476
16-74713553-C-G Hereditary spastic paraplegia 35 Benign (Jan 13, 2018)320477
16-74713670-C-T Hereditary spastic paraplegia 35 Likely benign (Jan 13, 2018)320478
16-74713684-G-C Hereditary spastic paraplegia 35 Uncertain significance (Jan 13, 2018)320479
16-74713685-C-A Hereditary spastic paraplegia 35 Uncertain significance (Jan 12, 2018)887808
16-74713743-G-A Hereditary spastic paraplegia 35 Uncertain significance (Jan 13, 2018)320480
16-74713786-A-T Hereditary spastic paraplegia 35 Benign (Jan 13, 2018)320481
16-74713799-G-A Hereditary spastic paraplegia 35 Uncertain significance (Jan 13, 2018)320482
16-74713888-C-T Hereditary spastic paraplegia 35 Uncertain significance (Jan 12, 2018)320483
16-74713907-C-G Hereditary spastic paraplegia 35 Benign (Jul 17, 2018)320484

GnomAD

Source: gnomAD

GeneTypeBio TypeTranscript Coding Exons Length
FA2Hprotein_codingprotein_codingENST00000219368 761877
pLI Probability
LOF Intolerant
pRec Probability
LOF Recessive
Individuals with
no LOFs
Individuals with
Homozygous LOFs
Individuals with
Heterozygous LOFs
Defined p
0.1470.8531257360111257470.0000437
Z-Score Observed Expected Observed/Expected Mutation Rate Total Possible in Transcript
Missense0.4561791970.9090.00001122378
Missense in Polyphen5168.9590.73957834
Synonymous-0.5229487.81.070.00000573734
Loss of Function2.96518.90.2650.00000107190

LoF frequencies by population

EthnicitySum of pLOFs p
African & African-American0.00009060.0000906
Ashkenazi Jewish0.000.00
East Asian0.00005440.0000544
Finnish0.000.00
European (Non-Finnish)0.00005290.0000527
Middle Eastern0.00005440.0000544
South Asian0.00003270.0000327
Other0.000.00

dbNSFP

Source: dbNSFP

Function
FUNCTION: Required for alpha-hydroxylation of free fatty acids and the formation of alpha-hydroxylated sphingolipids. {ECO:0000269|PubMed:15337768, ECO:0000269|PubMed:17355976}.;
Disease
DISEASE: Spastic paraplegia 35, autosomal recessive (SPG35) [MIM:612319]: A form of spastic paraplegia, a neurodegenerative disorder characterized by a slow, gradual, progressive weakness and spasticity of the lower limbs. Rate of progression and the severity of symptoms are quite variable. Initial symptoms may include difficulty with balance, weakness and stiffness in the legs, muscle spasms, and dragging the toes when walking. In some forms of the disorder, bladder symptoms (such as incontinence) may appear, or the weakness and stiffness may spread to other parts of the body. SPG35 is a complicated form characterized by childhood onset of gait difficulties. It has a rapid progression and many patients become wheelchair-bound as young adults. Patients manifest cognitive decline associated with leukodystrophy. Other variable neurologic features, such as dystonia, optic atrophy, and seizures may also occur. {ECO:0000269|PubMed:19068277, ECO:0000269|PubMed:20104589, ECO:0000269|PubMed:20853438}. Note=The disease is caused by mutations affecting the gene represented in this entry.;
Pathway
Metabolism of lipids;Metabolism;fatty acid α-oxidation III;Sphingolipid de novo biosynthesis;Sphingolipid metabolism (Consensus)

Recessive Scores

pRec
0.131

Intolerance Scores

loftool
0.0542
rvis_EVS
-0.25
rvis_percentile_EVS
35.99

Haploinsufficiency Scores

pHI
0.262
hipred
Y
hipred_score
0.749
ghis
0.516

Essentials

essential_gene_CRISPR
N
essential_gene_CRISPR2
N
essential_gene_gene_trap
N
gene_indispensability_pred
N
gene_indispensability_score
0.250

Gene Damage Prediction

AllRecessiveDominant
MendelianMediumMediumMedium
Primary ImmunodeficiencyMediumMediumMedium
CancerMediumMediumMedium

Mouse Genome Informatics

Gene name
Fa2h
Phenotype
behavior/neurological phenotype (the observable actions or reactions of mammalian organisms that are manifested through development and lifespan); vision/eye phenotype; nervous system phenotype (the observable morphological and physiological characteristics of the extensive, intricate network of electochemical structures in the body that is comprised of the brain, spinal cord, nerves, ganglia and parts of the receptor organs that are manifested through development and lifespan); endocrine/exocrine gland phenotype; integument phenotype (the observable morphological and physiological characteristics of the skin and its associated structures, such as the hair, nails, sweat glands, sebaceous glands and other secretory glands that are manifested through development and lifespan); homeostasis/metabolism phenotype;

Gene ontology

Biological process
sebaceous gland cell differentiation;fatty acid metabolic process;fatty acid biosynthetic process;glucosylceramide biosynthetic process;galactosylceramide biosynthetic process;sphingolipid biosynthetic process;lipid modification;central nervous system myelin maintenance;peripheral nervous system myelin maintenance;regulation of cell population proliferation;regulation of hair cycle;plasma membrane raft organization;ceramide biosynthetic process;oxidation-reduction process;establishment of skin barrier
Cellular component
endoplasmic reticulum;endoplasmic reticulum membrane;membrane;integral component of membrane;organelle membrane
Molecular function
iron ion binding;heme binding;fatty acid alpha-hydroxylase activity